Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Assets (2017 - 2025)

Historic Assets for Regenerative Medical Technology (RMTG) over the last 9 years, with Q3 2025 value amounting to $4.5 million.

  • Regenerative Medical Technology's Assets rose 4000.63% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 4000.63%. This contributed to the annual value of $3.8 million for FY2024, which is 3272.98% up from last year.
  • As of Q3 2025, Regenerative Medical Technology's Assets stood at $4.5 million, which was up 4000.63% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Assets ranged from a high of $17.1 million in Q3 2021 and a low of $964674.0 during Q1 2021
  • Moreover, its 5-year median value for Assets was $4.5 million (2025), whereas its average is $6.3 million.
  • As far as peak fluctuations go, Regenerative Medical Technology's Assets skyrocketed by 1691781.7% in 2021, and later crashed by 6436.87% in 2023.
  • Regenerative Medical Technology's Assets (Quarter) stood at $9.3 million in 2021, then decreased by 13.17% to $8.1 million in 2022, then crashed by 64.37% to $2.9 million in 2023, then soared by 32.73% to $3.8 million in 2024, then rose by 18.28% to $4.5 million in 2025.
  • Its Assets was $4.5 million in Q3 2025, compared to $4.5 million in Q2 2025 and $4.0 million in Q1 2025.